AHMEDABAD, India, April 23, 2015 /PRNewswire/ --
Etna Biotech, the Vaccine R & D subsidiary of Zydus, announced a collaborative program with the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, for advancing leishmaniasis research. Under a separate gift agreement, Etna Biotech also extended its support of the NIH leishmaniasis program by donating $240,000 for research. The program’s goal is to collaborate between NIAID’s Vector Molecular Biology Section and Etna Biotech, the Vaccine Research Center of Zydus in Italy, to investigate the importance of vector salivary proteins in a future leishmaniasis vaccine, and testing in natural models of parasite transmission a combination of Leishmania antigens with a sand fly salivary protein to develop a novel candidate vaccine against visceral leishmaniasis (VL).
Help employers find you! Check out all the jobs and post your resume.
